[1]
Hodges, T. R., Abbott, J. R., Little, A. J., Sarkar, D., Salovich, J. M., Howes, J. E., Akan, D. T., Sai, J., Arnold, A. L., Browning, C., Burns, M. C., Sobolik, T., Sun, Q., Beesetty, Y., Coker, J. A., Scharn, D., Stadtmueller, H., Rossanese, O. W., Phan, J., … Fesik, S. W. (2018). Discovery and Structure-Based Optimization of Benzimidazole-Derived Activators of SOS1-Mediated Nucleotide Exchange on RAS. Journal of Medicinal Chemistry, 61(19), 8875–8894.
https://doi.org/10.1021/acs.jmedchem.8b01108[2] Zhao, X. Z., Smith, S. J., Métifiot, M., Johnson, B. C., Marchand, C., Pommier, Y., Hughes, S. H., Burke, T. R., Jr (2014). Bicyclic 1-hydroxy-2-oxo-1,2-dihydropyridine-3-carboxamide-containing HIV-1 integrase inhibitors having high antiviral potency against cells harboring raltegravir-resistant integrase mutants. Journal of medicinal chemistry, 57(4), 1573–1582.
https://doi.org/10.1021/jm401902n
